Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
117M
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
82.5M
-
Shares change
-
+114K
-
Total reported value, excl. options
-
$197M
-
Value change
-
-$7.27M
-
Put/Call ratio
-
1.38
-
Number of buys
-
56
-
Number of sells
-
-92
-
Price
-
$2.39
Significant Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q1 2024
184 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share as of Q1 2024.
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82.5M shares
of 117M outstanding shares and own 70.53% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11.2M shares), Rubric Capital Management LP (10.4M shares), VANGUARD GROUP INC (10.1M shares), Temasek Holdings (Private) Ltd (7.38M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), CITADEL ADVISORS LLC (2.74M shares), MORGAN STANLEY (2.66M shares), BANK OF AMERICA CORP /DE/ (2.43M shares), GEODE CAPITAL MANAGEMENT, LLC (2.2M shares), and BARCLAYS PLC (2.07M shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.